Myeloma Patients Europe webinar on personalised medicines in myeloma

  Myeloma is the disease with the highest number of approved drugs over the last 15 years. Actually, the prognosis of the disease has been tripled. As myeloma is a very heterogeneous disease, not all treatments are suitable for each patient. The challenge now is to choose the right treatment for each individual patient in order to improve patient health outcomes, increase the value of new medicines to healthcare systems and reduce healthcare costs. With…

EHA 2019 myeloma highlights

  More than 12.600 people attended the European Hematology Association (EHA) Annual Meeting, the largest EHA Congress ever recorded with a growth of more than a thousand participants from last year. EHA 2019 was held from 13 to 16 June in Amsterdam, The Netherlands where 360 presentations and more than 1300 posters were presented to update the latest development in haematology.